Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine XR formulation bioequivalence and food effect study
NCT07253441Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (14 cohorts), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Plasma Concentration at Day 6, Area Under the Plasma Concentration-time Curve From Time 0 to Time t at Day 6 and 5 more. Started Aug 2024; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT07253441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253441.